Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

US FDA Sought Patient Viewpoint On Hemlibra's Benefit/Risk Profile

Jan 27 2018

• By Sue Sutter

Related Content

<em>Iclusig</em> Experience Reflects Regulatory Risk Inherent With Accelerated Approval

Dec 17 2013

Hemlibra Clinical Development Timeline

Jan 27 2018

Genentech's Hemlibra: Clinical Outcome Assessment Data Only Partially Swayed US FDA

Jan 27 2018

From Listening To Advising: The Maturation Of US FDA's Patient-Focused Drug Development Program

Jan 09 2018

Novo Hemophilia Drug's Postmarket Monitoring Plan Not Robust Enough – US Panel

Apr 05 2017

FDA Quietly Consults Patients To Understand <em>Vimizim's</em> Six-Minute Walk Significance

Dec 01 2014

Related Companies

Genentech, Inc.

Takeda Pharmaceutical Co. Ltd.

Novo Nordisk A/S

BioMarin Pharmaceutical Inc.

ARIAD Pharmaceuticals, Inc.

Additional Topics

United States Drug Review Rare Diseases Regulation Drug Review Profile BioPharmaceutical Blood & Coagulation Disorders

More from Drug Review Profiles

More from Product Reviews

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window